US equities
|
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
NVDA
$238.90
▲+2.12%
SPCX
$171.09
▲+7.63%
MU
$1,063.96
▼-1.02%
TSLA
$378.73
▲+2.20%
WBD
$30.95
▲+0.03%
MSFT
$525.18
▲+1.48%
AAPL
$332.89
▼-0.24%
META
$741.90
▲+1.90%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Global Coalition for Adaptive Research
Global Coalition for Adaptive Research in Collaboration with Cure Brain Cancer Foundation Announce the Opening of Glioblastoma Clinical Trial in Australia
November 14, 2023
From
Global Coalition for Adaptive Research
Via
Business Wire
Global Coalition for Adaptive Research Joins The South Pole Trek 4 Cancer to Raise Money for Cancer Research
November 02, 2023
From
Global Coalition for Adaptive Research
Via
Business Wire
Global Platform Study Presents Results to Guide Care of Severely Ill Patients With COVID-19 Using Routinely Available Drugs – Simvastatin and Vitamin C
October 25, 2023
From
Global Coalition for Adaptive Research
Via
Business Wire
Global Coalition for Adaptive Research and Polaris Group Announce Commencement of ADI-PEG 20 in GBM AGILE Trial
August 15, 2023
From
Global Coalition for Adaptive Research
Via
Business Wire
Global Coalition for Adaptive Research and GBM AGILE Partners to Ring The Nasdaq Stock Market Closing Bell in Honor of National Brain Tumor Awareness Month
May 19, 2023
From
Global Coalition for Adaptive Research
Via
Business Wire
Global Coalition for Adaptive Research Announces That Regorafenib Has Completed Follow-up in the GBM AGILE Trial for Patients With Glioblastoma
September 21, 2022
From
Global Coalition for Adaptive Research
Via
Business Wire
Global Coalition for Adaptive Research, Biohaven, and Vigeo Announce Commencement of Biohaven’s Troriluzole and Vigeo’S VT1021 in GBM AGILE Trial
July 06, 2022
From
Global Coalition for Adaptive Research
Via
Business Wire
Tickers
BHVN
Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Eritoran in REMAP-COVID
May 19, 2022
From
Global Coalition for Adaptive Research
Via
Business Wire
Global Coalition for Adaptive Research Announces Key Updates on GBM AGILE Phase 2-3 Adaptive Platform Trial for Patients With Glioblastoma
January 18, 2022
From
Global Coalition for Adaptive Research
Via
Business Wire
Ovarian CanceRx: New Innovative Clinical Research Effort Seeks to Accelerate the Development of New Treatments for Deadliest Gynecological Cancer
September 23, 2021
From
Global Coalition for Adaptive Research
Via
Business Wire
Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Apremilast in REMAP-COVID
July 12, 2021
From
Global Coalition for Adaptive Research
Via
Business Wire
